Showing results (71-80 of 126) with videos related to
Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|June 8, 2011
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinomaJoshua M Lang, Mahazarin R Kaikobad, Marianne Wallace, et al.Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.Clinical Genitourinary Cancer|July 10, 2013
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapyJoshua M Lang, Marianne Wallace, Jordan T Becker, et al.European Journal of Cancer (Oxford, England : 1990)|June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.Cancer|September 20, 2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials ConsortiumAndrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2005
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsHope S Rugo, Roy S Herbst, Glenn Liu, et al.Investigational New Drugs|July 18, 2013
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancerWilliam R Schelman, Tabraiz A Mohammed, Anne M Traynor, et al.Clinical Genitourinary Cancer|May 27, 2017
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])Roberto Pili, Opeyemi Jegede, Michael A Carducci, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancerGlenn Liu, Kurt Oettel, Gregory Ripple, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.Pageof 13